Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) have been given an average rating of “Buy” by the ten ratings firms that are covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $44.71.
Several research analysts have recently weighed in on DNTH shares. Lifesci Capital raised shares of Dianthus Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Baird R W raised shares of Dianthus Therapeutics to a “strong-buy” rating in a research report on Friday, July 26th. Wedbush lowered their price target on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Friday, August 9th. Cantor Fitzgerald assumed coverage on shares of Dianthus Therapeutics in a research report on Thursday, June 27th. They issued an “overweight” rating on the stock. Finally, Robert W. Baird assumed coverage on shares of Dianthus Therapeutics in a research report on Friday, July 26th. They issued an “outperform” rating and a $58.00 target price on the stock.
Read Our Latest Report on Dianthus Therapeutics
Institutional Trading of Dianthus Therapeutics
Dianthus Therapeutics Stock Down 0.4 %
Shares of DNTH opened at $28.00 on Wednesday. Dianthus Therapeutics has a 52-week low of $6.58 and a 52-week high of $33.77. The firm’s fifty day moving average is $28.00 and its two-hundred day moving average is $26.13. The stock has a market cap of $821.77 million, a PE ratio of -4.80 and a beta of 1.85.
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The business had revenue of $1.86 million for the quarter, compared to analyst estimates of $0.63 million. Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. As a group, research analysts anticipate that Dianthus Therapeutics will post -2.32 earnings per share for the current year.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Featured Articles
- Five stocks we like better than Dianthus Therapeutics
- Stock Market Sectors: What Are They and How Many Are There?
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- How to Calculate Return on Investment (ROI)
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Stock Splits, Do They Really Impact Investors?
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.